Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other ...

Wegovy-maker Novo Nordisk has implemented a global hiring freeze covering job roles that are not critical for its business, ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

Novo Nordisk’s wildly popular GLP-1 drug Wegovy has been approved for use against a serious form of liver disease.

At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

Novo Nordisk said on Friday the U.S. Food and Drug Administration has granted accelerated approval for its weight-loss drug ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...

Mumbai: In a serious security and public health concern, several consignments of Novo Nordisk’s injectable medicines — ...

The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the name-brand medicine. The company says it trying to stop them.